Medplus Health Services Ltd. (MEDPLUS) — Tipsheet

MedPlus targets 800 new stores in FY27, private label margins recover

Tipsheet Editorial — Thu, 21 May 2026 17:12:34 GMT

Management guides same-store sales growth of 9-10% annually and zero external debt. Private label contribution to rise 20-30 bps per quarter.

What’s new

Targets 800 net new store additions in FY27, accelerating from prior pace.
Private label growth to resume at 20-30 bps quarterly margin expansion.
Same-store sales growth guided at 9-10% annualized.

Why it matters

MedPlus has zero external debt, giving it financial flexibility to fund aggressive expansion. The specificity on private label margins and same-store growth provides a clear near-term earnings trajectory, making this concall more substantive than a routine update.

What we’re watching

Execution pace on 800 new stores amid competitive pharmacy landscape.
Whether private label margin expansion materializes as guided.
Consistency of same-store sales growth in a high-inflation environment.

The full read

MedPlus used its post-results concall to lay out a detailed growth roadmap. The centrepiece: 800 net new stores in FY27, a step up from recent run rates. That expansion is underpinned by zero external debt—all interest is lease-related under Ind AS, leaving the balance sheet clean for organic investment. Private label, a key margin lever, is expected to add 20-30 basis points per quarter after a pause. Same-store sales are pegged at 9-10% annual growth. The numbers are more concrete than typical guidance and give investors a clear benchmark to track. The open question is whether the pace of store additions can be sustained without cannibalising existing locations or pressuring unit economics.

Primary source: BSE · NSE

MedPlus profit jumps 46% as pharmacy margins expand

Tipsheet Editorial — Wed, 20 May 2026 21:18:28 GMT

Net profit hit ₹2.20 billion on 12% revenue growth for FY26. The board also shuffled its top ranks.

What’s new

FY26 net profit rose 46.1% to ₹2.20 billion on revenue of ₹68.92 billion.
The board re-appointed MD G. Madhukar Reddy for another five-year term from August 2026.
Two new independent directors joined; company secretary Manoj Kumar Srivastava resigned.

Why it matters

The profit growth significantly outpaced revenue growth, signalling a clear improvement in the company's cost structure. This is the financial performance that underpins the board's confidence to lock in the managing director for another five years.

What we’re watching

Whether the improved margins can sustain into FY27.
The strategy from the two new independent directors.
The reason for the company secretary's exit and succession plan.

The full read

MedPlus grew revenue 12.3% to ₹68.92 billion in FY26. Net profit surged 46.1% to ₹2.20 billion. The profit line moved almost four times as fast as the top line, a clear signal that the pharmacy chain's costs are under tighter control. That operational strength is the backdrop for the board's concurrent moves: re-instating Managing Director G. Madhukar Reddy for a fresh five-year term and adding two independent directors. The company secretary, Manoj Kumar Srivastava, exited the same day. The results are the strongest yet from the mid-cap retailer, but the real test is whether the margin gains can hold as the chain continues to expand its physical footprint.

Primary source: BSE · NSE

MedPlus profit jumps 46% to ₹2,196.1 mn, revenue up 12% to ₹68,924.6 mn

Tipsheet Editorial — Wed, 20 May 2026 21:07:09 GMT

Annual results show strong margin expansion; profit growth outpaces revenue by nearly 4x.

What’s new

Consolidated net profit rose 46.1% to ₹2,196.1 million for FY26.
Revenue grew 12.3% to ₹68,924.6 million.
Board reappointed the managing director for five years and appointed two new independent directors.

Why it matters

MedPlus is demonstrating that scale in pharmacy retail can drive margin expansion. With profit growth far exceeding revenue, the company shows improving operational efficiency. The governance changes ensure leadership continuity, though the company secretary's resignation is routine.

What we’re watching

Whether MedPlus can sustain this margin expansion in a competitive pharmacy market.
Impact of new independent directors on board governance.
Any updates on store expansion plans or online strategy in upcoming quarters.

The full read

MedPlus closed FY26 with net profit of ₹2,196.1 million, up 46.1% on revenue of ₹68,924.6 million, which grew 12.3%. The profit growth was nearly four times the revenue pace, indicating strong cost control and product mix improvement. The board renewed the managing director's tenure for five years and added two new independent directors, signaling stability. The company secretary resigned, a routine change. For a mid-cap pharmacy retailer, these results confirm that operational efficiency is improving as the network scales. The next test is whether this trajectory can hold as competition intensifies.

Primary source: BSE · NSE